US2008125371A1PendingUtilityA1

Specific antagonists for glucose-dependent insulinotropic polypeptide (GIP)

59
Assignee: WOLFE M MICHAELPriority: Dec 3, 1996Filed: Aug 15, 2006Published: May 29, 2008
Est. expiryDec 3, 2016(expired)· nominal 20-yr term from priority
Inventors:M. Michael WolfeChi-Chuan TsengLinda Neville
A61K 38/00A61P 3/10C07K 14/605
59
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

In one embodiment, this invention provides an antagonist of glucose-dependent insulinotropic polypeptide (GIP) consisting essentially of a 24 amino acid polypeptide corresponding to positions 7-30 of the sequence of GIP. In another embodiment, this invention provides a method of preventing and treating obesity and non-insulin dependent diabetes mellitus (Type II) in a patient comprising administering to the patient an antagonist of glucose-dependent insulinotropic polypeptide (GIP). In yet another embodiment, this invention provides a method of improving glucose tolerance in a mammal comprising administering to the mammal an antagonist of glucose-dependent insulinotropic polypeptide (GIP).

Claims

exact text as granted — not AI-modified
1 . An antagonist of glucose-dependent insulinotropic polypeptide (GIP) consisting essentially of a 24 amino acid polypeptide corresponding to positions 7-30 of the sequence of GIP. 
     
     
         2 . An isolated polypeptide comprising an amino acid sequence which specifically interferes with the biological activity of glucose-dependent insulinotropic polypeptide (GIP) when said polypeptide is administered to an animal in an amount effective to reduce intestinal uptake of glucose. 
     
     
         3 . A polypeptide according to  claim 2 , wherein said polypeptide comprises an amino acid identical to SEQ ID NO:2. 
     
     
         4 . A polypeptide according to  claim 2 , wherein the polypeptide comprises an amino acid sequence at least 95% identical to SEQ ID NO:2. 
     
     
         5 . A polypeptide according to  claim 2 , wherein said polypeptide comprises an amino acid sequence at least 95% identical to SEQ ID NO:8. 
     
     
         6 . A polypeptide according to  claim 2 , wherein the polypeptide comprises an amino acid sequence identical to SEQ ID NO:8. 
     
     
         7 . A polypeptide according to  claim 2 , wherein said polypeptide comprises an amino acid sequence at least 95% identical to SEQ ID NO:3. 
     
     
         8 . A polypeptide according to  claim 2 , wherein the polypeptide comprises an amino acid sequence at least 95% identical to SEQ ID NO:3. 
     
     
         9 . A polypeptide according to  claim 2 , wherein said polypeptide comprises an amino acid sequence identical to SEQ ID NO:9. 
     
     
         10 . A polypeptide according to  claim 2 , wherein the polypeptide comprises an amino acid sequence at least 95% identical to SEQ ID NO:9. 
     
     
         11 . A polypeptide according to  claim 2 , wherein said polypeptide comprises an amino acid sequence identical to SEQ ID NO:5. 
     
     
         12 . A polypeptide according to  claim 2 , wherein the polypeptide comprises an amino acid sequence at least 95% identical to SEQ ID NO:5. 
     
     
         13 . A polypeptide according to  claim 2 , wherein said polypeptide comprises an amino acid sequence identical to SEQ. ID NO 10. 
     
     
         14 . A polypeptide according to  claim 2 , wherein the polypeptide comprises an amino acid sequence at least 95% identical to SEQ ID NO:10. 
     
     
         15 . A polypeptide according to  claim 2 , wherein said polypeptide comprises an amino acid sequence identical to SEQ ID NO:13. 
     
     
         15 . A polypeptide according to  claim 2 , wherein the polypeptide comprises an amino acid sequence at least 95% identical to SEQ ID NO:13. 
     
     
         17 . A polypeptide according to  claim 2 , wherein said polypeptide comprises the amino acid sequence of SEQ ID NO:13. 
     
     
         18 . A polypeptide according to  claim 9 , wherein the polypeptide comprises an amino acid sequence at least 95% identical to SEQ ID NO:13. 
     
     
         19 . A polypeptide having an amino acid sequence which specifically interferes with the biological activity of glucose-dependent insulinotropic polypeptide (GIP) when said polypeptide is administered to a mammal in an amount effective to reduce absorption of glucose from the mammalian gut, said polypeptide comprising the amino acid sequence of SEQ ID NO 6. 
     
     
         20 . A polypeptide according to claim  39 , wherein the polypeptide comprises an amino acid sequence at least 95% identical to SEQ ID NO:2. 
     
     
         21 . An isolated polypeptide antagonist of glucose-dependent insulinotropic polypeptide (GIP) receptor effective to reduce glucose uptake from a mammalian intestine and reduce serum insulin levels.

Join the waitlist — get patent alerts

Track US2008125371A1 — get alerts on status changes and closely related new filings.

We store only your email — no account needed. See our privacy policy.